Skip to content
value.today

Ambu A/S: peers

Change the peers

Ambu A/S beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Ambu A/S, Demant A/S, Coloplast A/S, ConvaTec Group PLC, Bonesupport Holding AB (publ), Getinge AB: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Ambu A/S, Demant A/S, Coloplast A/S, ConvaTec Group PLC, NovoCure Limited, Bonesupport Holding AB (publ), Getinge AB, AtriCure, Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureAmbu A/Sbase
AMBU-B.CO · 🇩🇰 DK
Percentile in Healthcare
Percentile in Denmark
Demant A/S
DEMANT.CO · 🇩🇰 DK
Percentile in Healthcare
Percentile in Denmark
Coloplast A/S
COLO-B.CO · 🇩🇰 DK
Percentile in Healthcare
Percentile in Denmark
ConvaTec Group PLC
CTEC.L · 🇬🇧 GB
Percentile in Healthcare
Percentile in UK
NovoCure Limited
NVCR · 🇬🇧 GB
Percentile in Healthcare
Percentile in UK
Bonesupport Holding AB (publ)
BONEX.ST · 🇸🇪 SE
Percentile in Healthcare
Percentile in Sweden
Getinge AB
GETI-B.ST · 🇸🇪 SE
Percentile in Healthcare
Percentile in Sweden
AtriCure, Inc.
ATRC · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$3.2 BAug 1, 2026 · Market data5th of 8$9.5 BAug 1, 2026 · Market data2nd of 8$15.4 BAug 1, 2026 · Market data1st of 8$6.1 BAug 1, 2026 · Market data4th of 8$1.5 BOct 30, 2026 · Market data7th of 8$1.5 BAug 1, 2026 · Market data8th of 8$7.0 BAug 1, 2026 · Market data3rd of 8$3.1 BOct 29, 2026 · Market data6th of 8$4.6 B8 ranked
Revenue (Better neither way: ranked highest first)——————$2.4 BFY2025 · ESEF2nd of 4$655 MFY2025 · SEC3rd of 4——$3.6 BFY2025 · ESEF1st of 4$535 MFY2025 · SEC4th of 4$1.5 B4 ranked
Net income (Higher is better)——————$175 MFY2025 · ESEF2nd of 5$-136 MFY2025 · SEC5th of 5$14 MFY2025 · ESEF3rd of 5$230 MFY2025 · ESEF1st of 5$-11 MFY2025 · SEC4th of 5$14 M5 ranked
Employees (Better neither way: ranked highest first)3,500As on 2020 · Profile5th of 715,000As on 2019 · Profile2nd of 715,022As on June-2023 · Profile1st of 710,000As on 2023 · Profile4th of 71,023As on 2020 · Profile6th of 7——11,056As on 2022 · Profile3rd of 7875As on 2021 · Profile7th of 710,0007 ranked
Growth
Revenue growth (Higher is better)————————————+6.5%FY2025 · ESEF4th of 441st51st+8.3%FY2025 · SEC2nd of 445th62nd————+8.2%FY2025 · ESEF3rd of 445th57th+14.9%FY2025 · SEC1st of 459th71st+8.2%4 ranked
Revenue growth, 3 years a year (Higher is better)————————————————+6.8%FY2025 · SEC2nd of 246th59th————————+17.4%FY2025 · SEC1st of 268th82nd+12.1%2 ranked
Earnings per share growth (Higher is better)————————————-7.5%FY2025 · ESEF3rd of 329th30th————+14.0%FY2025 · ESEF2nd of 356th55th+48.4%FY2025 · ESEF1st of 375th86th————+14.0%3 ranked
Margins and returns
Gross margin (Higher is better)————————————56.2%FY2025 · ESEF3rd of 446th74th74.5%FY2025 · SEC2nd of 474th93rd————47.6%FY2025 · ESEF4th of 433rd67th75.0%FY2025 · SEC1st of 475th87th65.4%4 ranked
Operating margin (Higher is better)————————————13.0%FY2025 · ESEF1st of 478th62nd-23.5%FY2025 · SEC4th of 440th8th————10.8%FY2025 · ESEF2nd of 474th68th-1.8%FY2025 · SEC3rd of 455th37th4.5%4 ranked
Net margin (Higher is better)————————————7.2%FY2025 · ESEF1st of 474th62nd-20.8%FY2025 · SEC4th of 442nd10th————6.5%FY2025 · ESEF2nd of 472nd64th-2.1%FY2025 · SEC3rd of 457th38th2.2%4 ranked
Free cash flow margin (Higher is better)————————————————-11.6%FY2025 · SEC2nd of 241st8th————————9.0%FY2025 · SEC1st of 270th68th-1.3%2 ranked
Return on equity (Higher is better)————————————10.9%FY2025 · ESEF2nd of 582nd63rd-38.9%FY2025 · SEC5th of 549th9th18.1%FY2025 · ESEF1st of 589th81st7.4%FY2025 · ESEF3rd of 578th49th-2.4%FY2025 · SEC4th of 571st39th7.4%5 ranked
Valuation
P/E ratio (Better neither way: ranked highest first)226.1×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price38.5×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price19.2×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price34.8×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————105.1×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price24.6×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price210.1×price Oct 29, 2026 · Market dataonly one with it96th97th210.1×—
Price to sales (Better neither way: ranked highest first)4.8×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price2.6×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price3.6×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price2.5×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price2.1×price Oct 30, 2026 · Market data2nd of 234th34th————1.6×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price5.3×price Oct 29, 2026 · Market data1st of 258th78th3.7×2 ranked
Price to book (Better neither way: ranked highest first)3.4×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price5.5×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price7.6×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price4.0×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price4.5×price Oct 30, 2026 · Market data2nd of 264th71st16.1×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price1.9×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price6.4×price Oct 29, 2026 · Market data1st of 273rd81st5.4×2 ranked
Free cash flow yield (Higher is better)————————————————-4.9%price Oct 30, 2026 · Market data2nd of 254th25th1.5%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————1.5%price Oct 29, 2026 · Market data1st of 274th44th-1.7%2 ranked
Financial strength
Debt to equity (Lower is better)————————————————0.6×FY2025 · SEC2nd of 257th48th————————0.1×FY2025 · SEC1st of 225th18th0.3×2 ranked
Interest cover (Higher is better)————————————————-6.9×FY2025 · SEConly one with it50th24th————————————-6.9×—
Piotroski F-score (Higher is better)————————3 of 9FY2025 · SEC2nd of 2————7 of 9FY2025 · SEC1st of 25.0 of 92 ranked
Scorecard
Scorecard (Higher is better)——————3 of 5FY2025 · Scorecard3rd of 57 of 22FY2025 · Scorecard5th of 53 of 3FY2025 · Scorecard1st of 54 of 5FY2025 · Scorecard2nd of 512 of 23FY2025 · Scorecard4th of 560% passed5 ranked
Valuation checks (Higher is better)————————1 of 5FY2025 · Scorecard1st of 2————0 of 6FY2025 · Scorecard2nd of 210% passed2 ranked
Growth checks (Higher is better)——————1 of 2FY2025 · Scorecard5th of 54 of 6FY2025 · Scorecard4th of 51 of 1FY2025 · Scorecard1st of 52 of 2FY2025 · Scorecard1st of 55 of 6FY2025 · Scorecard3rd of 583% passed5 ranked
Profitability checks (Higher is better)——————2 of 3FY2025 · Scorecard2nd of 50 of 5FY2025 · Scorecard5th of 52 of 2FY2025 · Scorecard1st of 52 of 3FY2025 · Scorecard2nd of 51 of 5FY2025 · Scorecard4th of 567% passed5 ranked
Financial health checks (Higher is better)————————2 of 5FY2025 · Scorecard2nd of 2————5 of 5FY2025 · Scorecard1st of 270% passed2 ranked
Shareholder returns checks (Higher is better)————————0 of 1FY2025 · Scorecard2nd of 2————1 of 1FY2025 · Scorecard1st of 250% passed2 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)————————89.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 2————105.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 297.6%2 ranked
Institutions holding (Better neither way: ranked highest first)————————2422026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 2————2862026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 22642 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)————————+3.5 pp2026-Q2 against 2026-Q1 · 13F2nd of 2————+5.2 pp2026-Q2 against 2026-Q1 · 13F1st of 2+4.3 pp2 ranked

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Ambu A/S: How market caps are worked out; Demant A/S: How market caps are worked out; Coloplast A/S: How market caps are worked out; ConvaTec Group PLC: How market caps are worked out; NovoCure Limited: How market caps are worked out; Bonesupport Holding AB (publ): How market caps are worked out; Getinge AB: How market caps are worked out; AtriCure, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Ambu A/S———
Demant A/S———
Coloplast A/S———
ConvaTec Group PLC13.0%FY2025
78th percentile in Healthcaremedian -7.7%, 674 companies
62nd percentile in UKmedian 8.5%, 313 companies
NovoCure Limited-23.5%FY2025
40th percentile in Healthcaremedian -7.7%, 674 companies
8th percentile in UKmedian 8.5%, 313 companies
Bonesupport Holding AB (publ)———
Getinge AB10.8%FY2025
74th percentile in Healthcaremedian -7.7%, 674 companies
68th percentile in Swedenmedian 8.0%, 128 companies
AtriCure, Inc.-1.8%FY2025
55th percentile in Healthcaremedian -7.7%, 674 companies
37th percentile in USAmedian 3.5%, 2,594 companies

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$890 M$1.8 B$2.7 B$3.6 B20102012201420162018202020222024ConvaTec Group PLC $2.4 BNovoCure Limited $655 MGetinge AB $3.6 BAtriCure, Inc. $535 M

Rank in the group

1st2nd3rd4th2013201420152016201720182019202020212022202320242025ConvaTec Group PLC: 2nd of 4 in 2024ConvaTec Group PLC: 2nd of 4 in 2025ConvaTec Group PLCNovoCure Limited: 2nd of 2 in 2013NovoCure Limited: 2nd of 2 in 2014NovoCure Limited: 2nd of 2 in 2015NovoCure Limited: 2nd of 2 in 2016NovoCure Limited: 1st of 2 in 2017NovoCure Limited: 1st of 2 in 2018NovoCure Limited: 1st of 2 in 2019NovoCure Limited: 1st of 2 in 2020NovoCure Limited: 1st of 2 in 2021NovoCure Limited: 1st of 2 in 2022NovoCure Limited: 1st of 2 in 2023NovoCure Limited: 3rd of 4 in 2024NovoCure Limited: 3rd of 4 in 2025NovoCure LimitedGetinge AB: 1st of 4 in 2024Getinge AB: 1st of 4 in 2025Getinge ABAtriCure, Inc.: 1st of 2 in 2013AtriCure, Inc.: 1st of 2 in 2014AtriCure, Inc.: 1st of 2 in 2015AtriCure, Inc.: 1st of 2 in 2016AtriCure, Inc.: 2nd of 2 in 2017AtriCure, Inc.: 2nd of 2 in 2018AtriCure, Inc.: 2nd of 2 in 2019AtriCure, Inc.: 2nd of 2 in 2020AtriCure, Inc.: 2nd of 2 in 2021AtriCure, Inc.: 2nd of 2 in 2022AtriCure, Inc.: 2nd of 2 in 2023AtriCure, Inc.: 4th of 4 in 2024AtriCure, Inc.: 4th of 4 in 2025AtriCure, Inc.
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearAmbu A/SDemant A/SColoplast A/SConvaTec Group PLCNovoCure LimitedBonesupport Holding AB (publ)Getinge ABAtriCure, Inc.
2025———$2.4 BESEF2nd$655 MSEC3rd—$3.6 BESEF1st$535 MSEC4th
2024———$2.3 BESEF2nd$605 MSEC3rd—$3.3 BESEF1st$465 MSEC4th
2023————$509 MSEC1st——$399 MSEC2nd
2022————$538 MSEC1st——$330 MSEC2nd
2021————$535 MSEC1st——$274 MSEC2nd
2020————$494 MSEC1st——$207 MSEC2nd
2019————$351 MSEC1st——$231 MSEC2nd
2018————$248 MSEC1st——$202 MSEC2nd
2017————$177 MSEC1st——$175 MSEC2nd
2016————$83 MSEC2nd——$155 MSEC1st
2015————$33 MSEC2nd——$130 MSEC1st
2014————$15 MSEC2nd——$107 MSEC1st

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Ambu A/S#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Demant A/SDEMANT.CO · 🇩🇰 Denmark
    Same industry: Medical Instruments · Similar size: $9.5 B market cap against $3.2 B · Same country: Denmark · Ratios of the last two fiscal years on file
    Market cap $9.5 B (Aug 1, 2026) · revenue $3.6 B (year to December 2025)
    93 of 100 (industry or sector 50 + size 23 + country 15 + figures on file 5)
    In the group
  • Coloplast A/SCOLO-B.CO · 🇩🇰 Denmark
    Same industry: Medical Instruments · Similar size: $15.4 B market cap against $3.2 B · Same country: Denmark · Ratios of the last two fiscal years on file
    Market cap $15.4 B (Aug 1, 2026) · revenue $4.3 B (year to September 2024)
    90 of 100 (industry or sector 50 + size 20 + country 15 + figures on file 5)
    In the group
  • ConvaTec Group PLCCTEC.L · 🇬🇧 UK
    Same industry: Medical Instruments · Similar size: $6.1 B market cap against $3.2 B · Same region: Northern Europe · Ratios of the last two fiscal years on file
    Market cap $6.1 B (Aug 1, 2026) · revenue $2.4 B (year to December 2025)
    88 of 100 (industry or sector 50 + size 26 + country 7 + figures on file 5)
    In the group
  • NovoCure LimitedNVCR · 🇬🇧 UK
    Same industry: Medical Instruments · Similar size: $1.5 B market cap against $3.2 B · Same region: Northern Europe · Ratios of the last two fiscal years on file
    Market cap $1.5 B (Oct 30, 2026) · revenue $655 M (year to December 2025)
    87 of 100 (industry or sector 50 + size 25 + country 7 + figures on file 5)
    In the group
  • Bonesupport Holding AB (publ)BONEX.ST · 🇸🇪 Sweden
    Same industry: Medical Instruments · Similar size: $1.5 B market cap against $3.2 B · Same region: Northern Europe · Ratios of the last two fiscal years on file
    Market cap $1.5 B (Aug 1, 2026)
    87 of 100 (industry or sector 50 + size 25 + country 7 + figures on file 5)
    In the group
  • Getinge ABGETI-B.ST · 🇸🇪 Sweden
    Same industry: Medical Instruments · Similar size: $7.0 B market cap against $3.2 B · Same region: Northern Europe · Ratios of the last two fiscal years on file
    Market cap $7.0 B (Aug 1, 2026) · revenue $4.4 B (year to December 2025)
    87 of 100 (industry or sector 50 + size 25 + country 7 + figures on file 5)
    In the group
  • AtriCure, Inc.ATRC · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $3.1 B market cap against $3.2 B · Ratios of the last two fiscal years on file
    Market cap $3.1 B (Oct 29, 2026) · revenue $535 M (year to December 2025)
    85 of 100 (industry or sector 50 + size 30 + figures on file 5)
    In the group
  • Elekta AB (publ)EKTA-B.ST · 🇸🇪 Sweden
    Same industry: Medical Instruments · Similar size: $2.3 B market cap against $3.2 B · Same region: Northern Europe
    Market cap $2.3 B (Aug 1, 2026) · revenue $1.4 B (year to April 2022)
    85 of 100 (industry or sector 50 + size 28 + country 7)
    + Add
  • Biotage ABBIOT.ST · 🇸🇪 Sweden
    Same industry: Medical Instruments · Similar size: $1.0 B market cap against $3.2 B · Same region: Northern Europe · Ratios of the last two fiscal years on file
    Market cap $1.0 B (last known, Jan 5, 2024) · revenue $195 M (year to December 2024)
    85 of 100 (industry or sector 50 + size 23 + country 7 + figures on file 5)
    + Add
  • AddLife AB (publ)ALIF-B.ST · 🇸🇪 Sweden
    Same industry: Medical Instruments · Similar size: $2.1 B market cap against $3.2 B · Same region: Northern Europe
    Market cap $2.1 B (Aug 1, 2026) · revenue $847 M (year to December 2021)
    84 of 100 (industry or sector 50 + size 27 + country 7)
    + Add
  • Envista Holdings CorporationNVST · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $3.8 B market cap against $3.2 B · Ratios of the last two fiscal years on file
    Market cap $3.8 B (Oct 28, 2026) · revenue $2.7 B (year to December 2025)
    84 of 100 (industry or sector 50 + size 29 + figures on file 5)
    + Add
  • Pulse Biosciences, Inc.PLSE · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $3.9 B market cap against $3.2 B · Ratios of the last two fiscal years on file
    Market cap $3.9 B (Oct 27, 2026) · revenue $0 M (year to December 2025)
    84 of 100 (industry or sector 50 + size 29 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.